Associate Director
Revolution Medicines
Associate Director
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
Portfolio and Pipeline Strategy helps Revolution Medicines make clear choices as assets, indications, and investment options grow. The Associate Director of Portfolio Management is a late-stage, molecule-facing role that partners closely with Project Teams and Lifecycle Teams to build strong decision packages for pivotal development, registration, launch, and lifecycle decisions.
For material decisions, the role adds an enterprise portfolio perspective. It frames the broader questions around a molecule or indication, identifies dependencies and alternatives, and translates clinical, commercial, financial, and strategic insight into comparable portfolio inputs. The role works closely with Disease Area Strategy, asset, Commercial, Development, and Finance teams, as well as other relevant functions and governance partners, to support clear, well-informed decisions.
Key Responsibilities
Partner with assigned Project Teams and Lifecycle Teams to frame strategic questions and develop decision packages for pivotal development, registration, launch, indication, and lifecycle choices.
Partner with teams to develop the fact base for asset decisions—including target product profiles, evidence plans, probability of success, value scenarios, and development options—and translate these inputs into clear portfolio context and implications.
Integrate inputs from Development, Commercialization, Finance, Data and Analytics, Disease Area Strategy, and other relevant functions into clear decision briefs and recommendations.
Support teams in developing option sets, decision criteria, and Go/No-Go thresholds.
Apply asset, disease, and portfolio insight to late-stage and lifecycle choices, including pivotal-trial design, indication strategy, sequencing, and investment.
For material decisions, collaborate with teams to assess strategic fit, feasibility, capacity and timing dependencies, competing investments, and what an option enables or displaces.
Contribute molecule and indication insights to portfolio reviews, scenarios, path-to-ambition analyses, and prioritization recommendations.
Identify when a decision requires broader enterprise perspective and coordinate with portfolio leadership to develop the appropriate analysis.
Build trusted working relationships with program and functional leaders through rigorous analysis, constructive challenge, and practical support.
Required Skills, Experience and Education:
8 or more years of experience in biotechnology or pharmaceuticals, with experience in drug development, program leadership, portfolio planning, commercialization, strategy, or a closely related field.
Strong understanding of late-stage development, registration, commercialization, and lifecycle planning, including the decisions that shape pivotal trials, indication strategy, sequencing, and investment choices.
Demonstrated ability to frame complex strategic questions, develop options, assess trade-offs and portfolio implications, and communicate recommendations to senior stakeholders.
Experience working across Development, Regulatory, Commercialization, Finance, Data and Analytics, Disease Area Strategy, and other relevant functions to develop a common decision package.
Strong analytical skills and comfort working with clinical, market, financial, probability-of-success, and portfolio inputs.
Excellent interpersonal and influencing skills, with the ability to build trusted relationships and operate effectively in a highly cross-functional, evolving environment.
Preferred Skills:
Experience in oncology drug development and commercialization.
Experience supporting major investment decisions, indication prioritization, portfolio scenarios, or external opportunity assessment.
Advanced degree preferred, such as an M.S., MBA, Ph.D., M.D., or comparable degree in life sciences, medicine, business, or a related field.
#lLI-EM1 #LI-Hybrid
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Base Pay Salary Range 186000 - 233000 USD
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines